Lumos Pharma (LUMO) Stock Forecast, Price Target & Predictions
LUMO Stock Forecast
Lumos Pharma stock forecast is as follows: an average price target of $16.50 (represents a 273.30% upside from LUMO’s last price of $4.42) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
LUMO Price Target
LUMO Analyst Ratings
Lumos Pharma Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 08, 2022 | - | Jefferies | $7.00 | $4.46 | 56.95% | 58.37% |
May 10, 2022 | Yasmeen Rahimi | Piper Sandler | $26.00 | $8.05 | 222.98% | 488.24% |
Lumos Pharma Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $4.42 | $4.42 | $4.42 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 24, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
Sep 24, 2024 | EF Hutton | - | Buy | Initialise |
May 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Nov 14, 2022 | Jefferies | - | Hold | Downgrade |
May 10, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Lumos Pharma Financial Forecast
Lumos Pharma Revenue Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.00K | $527.00K | $691.00K | $512.00K | $497.00K | $403.00K | $111.00K | $40.00K | $74.00K |
Avg Forecast | $1.21M | $1.15M | $1.09M | $1.04M | $989.49K | $940.77K | $894.45K | $850.41K | $808.54K | $768.73K | $730.88K | $694.89K | $150.00K | $150.00K | $150.00K | $150.00K | $5.34M | $255.75K | $265.00K | $300.00K | $1.75K | $225.40K | $365.17K | $222.40K | $114.33K | $66.67K | $18.50K | $107.26K | $25.00K | $2.60M |
High Forecast | $1.21M | $1.15M | $1.09M | $1.04M | $989.49K | $940.77K | $894.45K | $850.41K | $808.54K | $768.73K | $730.88K | $694.89K | $150.00K | $150.00K | $150.00K | $150.00K | $5.34M | $255.75K | $265.00K | $300.00K | $1.75K | $225.60K | $365.17K | $222.40K | $114.33K | $66.67K | $18.50K | $128.71K | $25.00K | $2.60M |
Low Forecast | $1.21M | $1.15M | $1.09M | $1.04M | $989.49K | $940.77K | $894.45K | $850.41K | $808.54K | $768.73K | $730.88K | $694.89K | $150.00K | $150.00K | $150.00K | $150.00K | $5.34M | $255.75K | $265.00K | $300.00K | $1.75K | $225.20K | $365.17K | $222.40K | $114.33K | $66.67K | $18.50K | $85.81K | $25.00K | $2.60M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 11 | 9 | 9 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 1.44% | 3.11% | 4.48% | 7.45% | 21.78% | 1.03% | 1.60% | 0.03% |
Lumos Pharma EBITDA Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 11 | 9 | 9 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.93M | $-9.64M | $-8.03M | $-9.22M | $-7.25M | $-7.84M | $-7.71M | $-6.86M | $-512.00K |
Avg Forecast | $-1.21M | $-1.15M | $-1.09M | $-1.04M | $-989.49K | $-940.77K | $-894.45K | $-850.41K | $-808.54K | $-768.73K | $-730.88K | $-694.89K | $-150.00K | $-150.00K | $-150.00K | $-150.00K | $-5.34M | $-255.75K | $-265.00K | $-300.00K | $-1.75K | $-225.40K | $-365.17K | $-222.40K | $-114.33K | $-66.67K | $-18.50K | $-7.44M | $-25.00K | $-2.60M |
High Forecast | $-1.21M | $-1.15M | $-1.09M | $-1.04M | $-989.49K | $-940.77K | $-894.45K | $-850.41K | $-808.54K | $-768.73K | $-730.88K | $-694.89K | $-150.00K | $-150.00K | $-150.00K | $-150.00K | $-5.34M | $-255.75K | $-265.00K | $-300.00K | $-1.75K | $-225.20K | $-365.17K | $-222.40K | $-114.33K | $-66.67K | $-18.50K | $-5.95M | $-25.00K | $-2.60M |
Low Forecast | $-1.21M | $-1.15M | $-1.09M | $-1.04M | $-989.49K | $-940.77K | $-894.45K | $-850.41K | $-808.54K | $-768.73K | $-730.88K | $-694.89K | $-150.00K | $-150.00K | $-150.00K | $-150.00K | $-5.34M | $-255.75K | $-265.00K | $-300.00K | $-1.75K | $-225.60K | $-365.17K | $-222.40K | $-114.33K | $-66.67K | $-18.50K | $-8.93M | $-25.00K | $-2.60M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.63% | 26.41% | 36.09% | 80.69% | 108.70% | 424.00% | 1.04% | 274.32% | 0.20% |
Lumos Pharma Net Income Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 11 | 9 | 9 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.30M | $-8.93M | $-6.66M | $-7.67M | $-6.95M | $-7.76M | $-7.71M | $-2.42M | $1.76M |
Avg Forecast | $-1.58M | $-1.42M | $-1.32M | $-1.39M | $-1.85M | $-1.66M | $-1.55M | $-1.63M | $-2.07M | $-1.87M | $-1.73M | $-2.74M | $-2.41M | $-2.78M | $-2.47M | $-2.42M | $-3.73M | $-6.00M | $-9.52M | $-9.22M | $-9.23M | $-9.31M | $-8.90M | $-9.05M | $-7.56M | $-8.18M | $-8.00M | $-7.46M | $-6.99M | $-5.23M |
High Forecast | $-1.58M | $-1.42M | $-1.32M | $-1.39M | $-1.85M | $-1.66M | $-1.55M | $-1.63M | $-2.07M | $-1.87M | $-1.73M | $-2.74M | $-2.41M | $-2.78M | $-2.47M | $-2.42M | $-3.73M | $-1.93M | $-9.52M | $-9.22M | $-8.68M | $-9.31M | $-8.90M | $-9.05M | $-7.56M | $-8.18M | $-8.00M | $-5.97M | $-6.99M | $-5.23M |
Low Forecast | $-1.58M | $-1.42M | $-1.32M | $-1.39M | $-1.85M | $-1.66M | $-1.55M | $-1.63M | $-2.07M | $-1.87M | $-1.73M | $-2.74M | $-2.41M | $-2.78M | $-2.47M | $-2.42M | $-3.73M | $-9.96M | $-9.52M | $-9.22M | $-10.09M | $-9.31M | $-8.90M | $-9.05M | $-7.56M | $-8.18M | $-8.00M | $-8.95M | $-6.99M | $-5.23M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 1.00% | 0.74% | 1.02% | 0.85% | 0.97% | 1.03% | 0.35% | -0.34% |
Lumos Pharma SG&A Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 11 | 9 | 9 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.89M | $4.15M | $4.36M | $4.49M | $3.92M | $3.68M | $3.62M | $4.63M | $5.16M |
Avg Forecast | $51.66M | $49.11M | $46.69M | $44.40M | $42.21M | $40.13M | $38.16M | $36.28M | $34.49M | $32.79M | $31.18M | $29.64M | $6.40M | $6.40M | $6.40M | $6.40M | $227.61M | $10.91M | $11.30M | $12.80M | $74.65K | $9.62M | $15.58M | $9.49M | $4.88M | $2.84M | $789.17K | $4.58M | $1.07M | $110.91M |
High Forecast | $51.66M | $49.11M | $46.69M | $44.40M | $42.21M | $40.13M | $38.16M | $36.28M | $34.49M | $32.79M | $31.18M | $29.64M | $6.40M | $6.40M | $6.40M | $6.40M | $227.61M | $10.91M | $11.30M | $12.80M | $74.65K | $9.62M | $15.58M | $9.49M | $4.88M | $2.84M | $789.17K | $5.49M | $1.07M | $110.91M |
Low Forecast | $51.66M | $49.11M | $46.69M | $44.40M | $42.21M | $40.13M | $38.16M | $36.28M | $34.49M | $32.79M | $31.18M | $29.64M | $6.40M | $6.40M | $6.40M | $6.40M | $227.61M | $10.91M | $11.30M | $12.80M | $74.65K | $9.61M | $15.58M | $9.49M | $4.88M | $2.84M | $789.17K | $3.66M | $1.07M | $110.91M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.40% | 0.27% | 0.46% | 0.92% | 1.38% | 4.67% | 0.79% | 4.34% | 0.05% |
Lumos Pharma EPS Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 4 | 11 | 9 | 9 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.04 | $-0.00 | $-0.81 | $-0.92 | $-0.83 | $-0.93 | $-0.92 | $-0.29 | $0.21 |
Avg Forecast | $-0.19 | $-0.18 | $-0.16 | $-0.17 | $-0.23 | $-0.21 | $-0.19 | $-0.20 | $-0.26 | $-0.23 | $-0.21 | $-0.34 | $-0.30 | $-0.34 | $-0.30 | $-0.30 | $-0.46 | $-0.74 | $-1.17 | $-1.14 | $-1.14 | $-1.15 | $-1.10 | $-1.11 | $-0.93 | $-1.01 | $-0.99 | $-0.89 | $-0.86 | $-0.65 |
High Forecast | $-0.19 | $-0.18 | $-0.16 | $-0.17 | $-0.23 | $-0.21 | $-0.19 | $-0.20 | $-0.26 | $-0.23 | $-0.21 | $-0.34 | $-0.30 | $-0.34 | $-0.30 | $-0.30 | $-0.46 | $-0.24 | $-1.17 | $-1.14 | $-1.07 | $-1.15 | $-1.10 | $-1.11 | $-0.93 | $-1.01 | $-0.99 | $-0.89 | $-0.86 | $-0.65 |
Low Forecast | $-0.19 | $-0.18 | $-0.16 | $-0.17 | $-0.23 | $-0.21 | $-0.19 | $-0.20 | $-0.26 | $-0.23 | $-0.21 | $-0.34 | $-0.30 | $-0.34 | $-0.30 | $-0.30 | $-0.46 | $-1.23 | $-1.17 | $-1.14 | $-1.24 | $-1.15 | $-1.10 | $-1.11 | $-0.93 | $-1.01 | $-0.99 | $-0.89 | $-0.86 | $-0.65 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.00% | 0.73% | 0.99% | 0.82% | 0.94% | 1.03% | 0.34% | -0.33% |
Lumos Pharma Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
STTK | Shattuck Labs | $1.16 | $12.00 | 934.48% | Hold |
LUMO | Lumos Pharma | $4.42 | $16.50 | 273.30% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
LUMO Forecast FAQ
Is Lumos Pharma a good buy?
Yes, according to 5 Wall Street analysts, Lumos Pharma (LUMO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of LUMO's total ratings.
What is LUMO's price target?
Lumos Pharma (LUMO) average price target is $16.5 with a range of $7 to $26, implying a 273.30% from its last price of $4.42. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lumos Pharma stock go up soon?
According to Wall Street analysts' prediction for LUMO stock, the company can go up by 273.30% (from the last price of $4.42 to the average price target of $16.5), up by 488.24% based on the highest stock price target, and up by 58.37% based on the lowest stock price target.
Can Lumos Pharma stock reach $7?
LUMO's average twelve months analyst stock price target of $16.5 supports the claim that Lumos Pharma can reach $7 in the near future.
What are Lumos Pharma's analysts' financial forecasts?
Lumos Pharma's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $3.68M (high $3.68M, low $3.68M), average EBITDA is $-3.675M (high $-3.675M, low $-3.675M), average net income is $-6.689M (high $-6.689M, low $-6.689M), average SG&A $156.77M (high $156.77M, low $156.77M), and average EPS is $-0.825 (high $-0.825, low $-0.825). LUMO's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $4.5M (high $4.5M, low $4.5M), average EBITDA is $-4.498M (high $-4.498M, low $-4.498M), average net income is $-5.709M (high $-5.709M, low $-5.709M), average SG&A $191.86M (high $191.86M, low $191.86M), and average EPS is $-0.704 (high $-0.704, low $-0.704).
Did the LUMO's actual financial results beat the analysts' financial forecasts?
Based on Lumos Pharma's last annual report (Dec 2023), the company's revenue was $2.05M, beating the average analysts forecast of $814.72K by 151.74%. Apple's EBITDA was $-36.614M, beating the average prediction of $-815K by 4394.08%. The company's net income was $-34.034M, missing the average estimation of $-36.488M by -6.72%. Apple's SG&A was $16.57M, missing the average forecast of $34.75M by -52.33%. Lastly, the company's EPS was $-0.0042, missing the average prediction of $-4.498 by -99.91%. In terms of the last quarterly report (Sep 2023), Lumos Pharma's revenue was $7K, missing the average analysts' forecast of $225.4K by -96.89%. The company's EBITDA was $-8.932M, beating the average prediction of $-225K by 3862.73%. Lumos Pharma's net income was $-8.3M, missing the average estimation of $-9.313M by -10.88%. The company's SG&A was $3.89M, missing the average forecast of $9.62M by -59.51%. Lastly, the company's EPS was $-1.04, missing the average prediction of $-1.148 by -9.41%